Canagliflozin
Authors:
- 1 September 2014
- journal article
- research article
- Published by Wolters Kluwer Health in JAAPA
- Vol. 27 (9) , 47-50
Abstract
Canagliflozin is a sodium glucose cotransporter 2 inhibitor for patients with type 2 diabetes and can be given as monotherapy or in combination with other agents, including insulin. Taken orally once daily, canagliflozin can reduce weight and BP, but has been associated with genital mycotic infections.Keywords
This publication has 12 references indexed in Scilit:
- Standards of Medical Care in Diabetes—2014Diabetes Care, 2013
- Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trialAmerican Heart Journal, 2013
- Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 DiabetesDiabetes Care, 2013
- Efficacy and Safety of Canagliflozin Treatment in Older Subjects With Type 2 Diabetes Mellitus: A Randomized TrialHospital Practice, 2013
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney diseaseDiabetes, Obesity and Metabolism, 2013
- Aace Comprehensive Diabetes Management Algorithm 2013Endocrine Practice, 2013
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetes, Obesity and Metabolism, 2013
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered ApproachDiabetes Care, 2012
- Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 DiabetesDiabetes Care, 2012
- Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implicationsDiabetic Medicine, 2010